112 related articles for article (PubMed ID: 11417445)
1. CYP2C19 polymorphism is not important for the in vivo metabolism of selegiline.
Laine K; Anttila M; Nyman L; Wahlberg A; Bertilsson L
Eur J Clin Pharmacol; 2001 May; 57(2):137-42. PubMed ID: 11417445
[TBL] [Abstract][Full Text] [Related]
2. Selegiline metabolism and cytochrome P450 enzymes: in vitro study in human liver microsomes.
Taavitsainen P; Anttila M; Nyman L; Karnani H; Salonen JS; Pelkonen O
Pharmacol Toxicol; 2000 May; 86(5):215-21. PubMed ID: 10862503
[TBL] [Abstract][Full Text] [Related]
3. CYP2D6 polymorphism is not crucial for the disposition of selegiline.
Scheinin H; Anttila M; Dahl ML; Karnani H; Nyman L; Taavitsainen P; Pelkonen O; Bertilsson L
Clin Pharmacol Ther; 1998 Oct; 64(4):402-11. PubMed ID: 9797797
[TBL] [Abstract][Full Text] [Related]
4. Multiple-dose pharmacokinetics of selegiline and desmethylselegiline suggest saturable tissue binding.
Laine K; Anttila M; Huupponen R; Mäki-Ikola O; Heinonen E
Clin Neuropharmacol; 2000; 23(1):22-7. PubMed ID: 10682227
[TBL] [Abstract][Full Text] [Related]
5. Selegiline pharmacokinetics are unaffected by the CYP3A4 inhibitor itraconazole.
Kivistö KT; Wang JS; Backman JT; Nyman L; Taavitsainen P; Anttila M; Neuvonen PJ
Eur J Clin Pharmacol; 2001 Apr; 57(1):37-42. PubMed ID: 11372588
[TBL] [Abstract][Full Text] [Related]
6. A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition.
Clarke A; Brewer F; Johnson ES; Mallard N; Hartig F; Taylor S; Corn TH
J Neural Transm (Vienna); 2003 Nov; 110(11):1241-55. PubMed ID: 14628189
[TBL] [Abstract][Full Text] [Related]
7. P450 phenotyping of the metabolism of selegiline to desmethylselegiline and methamphetamine.
Benetton SA; Fang C; Yang YO; Alok R; Year M; Lin CC; Yeh LT
Drug Metab Pharmacokinet; 2007 Apr; 22(2):78-87. PubMed ID: 17495414
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and bioequivalence of the main metabolites of selegiline: desmethylselegiline, methamphetamine and amphetamine after oral administration of selegiline.
Mascher HJ; Kikuta C; Millendorfer A; Schiel H; Ludwig G
Int J Clin Pharmacol Ther; 1997 Jan; 35(1):9-13. PubMed ID: 9021435
[TBL] [Abstract][Full Text] [Related]
9. Desmethylselegiline, a metabolite of selegiline, is an irreversible inhibitor of monoamine oxidase type B in humans.
Heinonen EH; Anttila MI; Karnani HL; Nyman LM; Vuorinen JA; Pyykkö KA; Lammintausta RA
J Clin Pharmacol; 1997 Jul; 37(7):602-9. PubMed ID: 9243353
[TBL] [Abstract][Full Text] [Related]
10. CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences.
Tamminga WJ; Wemer J; Oosterhuis B; Weiling J; Wilffert B; de Leij LF; de Zeeuw RA; Jonkman JH
Eur J Clin Pharmacol; 1999 May; 55(3):177-84. PubMed ID: 10379632
[TBL] [Abstract][Full Text] [Related]
11. Effect of concomitant hormone replacement therapy containing estradiol and levonorgestrel on the pharmacokinetics of selegiline.
Palovaara S; Anttila M; Nyman L; Laine K
Eur J Clin Pharmacol; 2002 Jul; 58(4):259-63. PubMed ID: 12136372
[TBL] [Abstract][Full Text] [Related]
12. Integrated pharmacokinetic and metabolic modeling of selegiline and metabolites after transdermal administration.
Rohatagi S; Barrett JS; DeWitt KE; Morales RJ
Biopharm Drug Dispos; 1997 Oct; 18(7):567-84. PubMed ID: 9330778
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of selegiline, R-methamphetamine, R-amphetamine, and desmethylselegiline in oral fluid after a single oral administration of selegiline.
Chen L; Shen B; Wang S; Yu Y; Yan H; Shi Y; Duan G; Xiang P
Drug Test Anal; 2019 Jun; 11(6):898-905. PubMed ID: 30614204
[TBL] [Abstract][Full Text] [Related]
14. Absorption and presystemic metabolism of selegiline hydrochloride at different regions in the gastrointestinal tract in healthy males.
Barrett JS; Szego P; Rohatagi S; Morales RJ; De Witt KE; Rajewski G; Ireland J
Pharm Res; 1996 Oct; 13(10):1535-40. PubMed ID: 8899847
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites.
Heinonen EH; Anttila MI; Lammintausta RA
Clin Pharmacol Ther; 1994 Dec; 56(6 Pt 2):742-9. PubMed ID: 7995016
[TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacokinetics and pharmacodynamics of selegiline. An update.
Mahmood I
Clin Pharmacokinet; 1997 Aug; 33(2):91-102. PubMed ID: 9260033
[TBL] [Abstract][Full Text] [Related]
17. Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to S-mephenytoin 4'-hydroxylation phenotype and genotype.
Tanaka M; Ohkubo T; Otani K; Suzuki A; Kaneko S; Sugawara K; Ryokawa Y; Hakusui H; Yamamori S; Ishizaki T
Clin Pharmacol Ther; 1997 Dec; 62(6):619-28. PubMed ID: 9433390
[TBL] [Abstract][Full Text] [Related]
18. Bioavailability of two selegiline hydrochloride tablet products.
Müller FO; Schall R; Hundt HK; Joubert A; Middle MV; Muir AR; Duursema L; Groenewoud G; Swart KJ
Arzneimittelforschung; 1996 Nov; 46(11):1037-40. PubMed ID: 8955861
[TBL] [Abstract][Full Text] [Related]
19. P-hydroxylation of phenobarbital: relationship to (S)-mephenytoin hydroxylation (CYP2C19) polymorphism.
Hadama A; Ieiri I; Morita T; Kimura M; Urae A; Irie S; Kaneda T; Mamiya K; Tashiro N; Higuchi S; Otsubo K
Ther Drug Monit; 2001 Apr; 23(2):115-8. PubMed ID: 11294510
[TBL] [Abstract][Full Text] [Related]
20. A methodological investigation on the estimation of the S-mephenytoin hydroxylation phenotype using the urinary S/R ratio.
Tybring G; Bertilsson L
Pharmacogenetics; 1992 Oct; 2(5):241-3. PubMed ID: 1306124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
